Myeloperoxidase up-regulation during haemodialysis: Is heparin the missing link? [7]

Nephrology Dialysis Transplantation

Volumn 21, Issue 4, 2006, Pages 1128-

  Borawski, Jacek ^a   Naumnik, Beata ^a   Rydzewska Rosołowska, Alicja ^a   Myśliwiec, Michał ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CITRATE TRISODIUM; DALTEPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE; NAFAMSTAT MESILATE;

ANTICOAGULATION; DEGRANULATION; DIALYSATE; ENZYME BLOOD LEVEL; HEMODIALYSIS; HUMAN; LETTER; NEUTROPHIL CHEMOTAXIS; OXIDATIVE STRESS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

HEPARIN; HUMANS; OXIDATIVE STRESS; PEROXIDASE; RENAL DIALYSIS; UP-REGULATION;

EID: 33645282501     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfl002     Document Type: Letter

References (6)

1. Wu CC, Chen JS, Wu WM et al. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible membranes. Nephrol Dial Transplant 2005; 20: 1134-1139
2. Gritters M, Grooteman MPC, Schoorl M et al. Citrate anticoagulation abolishes degranulation of polymorphonuclear cells and platelets and reduces oxidative stress during haemodialysis. Nephrol Dial Transplant 2006; 21: 153-159
3. Krieter DH, Lemke HD, Wanner C. Myeloperoxidase serves as a marker of oxidative stress during single haemodialysis session using two different biocompatible membranes. Nephrol Dial Transplant 2006; 21: 546
4. Inose K, Ono K, Tsuchida A et al. Active inhibitory effect of nafamostat mesylate against the elevation of plasma myeloperoxidase during hemodialysis. Nephron 1997; 75: 420-425
5. Wu CC, Lin SH, Lin YF. Reply. Nephrol Dial Transplant 2006; 21: 546
6. Borawski J. Myeloperoxidase as a marker of hemodialysis biocompatibility and oxidative stress: The underestimated modifying effects of heparin. Am J Kidney Dis 2006; 47: 37-41